Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.030 AUD
−6.94 M AUD
4.90 M AUD
191.84 M
About IMMURON LIMITED
Sector
CEO
Steven Lydeamore
Headquarters
Blackburn North
Website
Founded
1994
ISIN
AU000000IMC7
FIGI
BBG000C6G8P0
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IMC is 0.086 AUD — it hasn't changed in the past 24 hours. Watch IMMURON LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange IMMURON LIMITED stocks are traded under the ticker IMC.
IMC stock has risen by 2.60% compared to the previous week, the month change is a 1.28% rise, over the last year IMMURON LIMITED has showed a 1.18% increase.
We've gathered analysts' opinions on IMMURON LIMITED future price: according to them, IMC price has a max estimate of 0.19 AUD and a min estimate of 0.19 AUD. Watch IMC chart and read a more detailed IMMURON LIMITED stock forecast: see what analysts think of IMMURON LIMITED and suggest that you do with its stocks.
IMC stock is 8.54% volatile and has beta coefficient of 1.72. Track IMMURON LIMITED stock price on the chart and check out the list of the most volatile stocks — is IMMURON LIMITED there?
Yes, you can track IMMURON LIMITED financials in yearly and quarterly reports right on TradingView.
IMMURON LIMITED is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IMC net income for the last half-year is −4.86 M AUD, while the previous report showed −2.07 M AUD of net income which accounts for −134.60% change. Track more IMMURON LIMITED financial stats to get the full picture.
No, IMC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMURON LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMURON LIMITED technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMURON LIMITED stock shows the sell signal. See more of IMMURON LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.